The Cancer Effect is the inspiring true story of one woman’s journey with cancer, written to provide hope and healing for patients, survivors, and those who love them. Moving, enlightening, uplifting, and honest. Learn more about this powerful memoir at www.claudiabretzing.com Non-fiction/self help
Leveraging 130 years of knowledge and expertise across the Johnson & Johnson Family of Companies, Johnson & Johnson Medical Devices (JJMD) is proud to launch a new approach to help drive value-based healthcare in hospitals across Europe, Middle East and Africa (EMEA) – CareAdvantage. This is a data-driven, holistic approach in which JJMD partners with hospitals and other healthcare providers to provide a range of benefits, tailored to the customer’s specific needs and priorities.
The healthcare marketplace is changing, with intensifying pressure to meet the ‘triple aim’ of improving outcomes, increasing patient satisfaction and reducing costs. As the focus shifts from volume to value, there is a growing need for new delivery models, resulting in rapid transformation for hospital systems, clinicians and their patients.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8119051-johnson-medical-devices-careadvantage/
The thinking that diet does not affect acne is a falsehood perpetuated by that part of the medical industry that is trying to protect their livelihood of dispensing drugs. The AMA has established that the only way to deal with acne is through the use of medication. They say there is no evidence to support the idea that diet causes acne.
The European Head and Neck Society (EHNS) and the Make Sense Campaign, today announced the launch of the Third Annual Head and Neck Cancer Awareness week (21–25 September). Through the pan-European Awareness Week, the EHNS and Make Sense Campaign promote education on head and neck cancer risk factors, disease prevention and disease signs and symptoms for both patients and healthcare professionals.
“Each year 350,000 people are diagnosed with head and neck cancer across Europe, and over half will not be alive after five years. However, if diagnosed and treated earlier, patients can have an 80 – 90% survival rate.” said Professor René Leemans, President of the EHNS and Professor and Chief of Otolaryngology – Head and Neck Surgery at VU University Medical Centre. “Through the Make Sense Campaign we are educating people about the early signs of the disease and encouraging them to seek professional help in a timely manner. Additionally, we are advocating for the best possible standards of patient care so that their outcomes can be optimised once they have been diagnosed with the disease.”
To view the multimedia release go to:
http://www.multivu.com/players/uk/7628151-support-head-neck-cancer-patients/
Global specialty plastics provider Eastman demonstrates the dominant performance of next-generation material Eastman MXF221 copolyester as a disinfectant-ready polymer for safer healthcare environments at the Medical Design & Manufacturing (MD&M) West trade show in Anaheim, California, Feb. 6 to 8. The latest advancement in biocompatible medical-grade polymers for medical device housings and hardware, Eastman MXF221 offers unsurpassed chemical compatibility with stringent disinfectants used to combat healthcare-associated infections (HAIs) as well as improved durability and impact strength.
To view the multimedia release go to:
https://www.multivu.com/players/English/8261151-eastman-disinfectant-ready-polymer-mdm-west/
Medical, health, technology, healthcare, treatment, Richard Fechter, interview, trade show, MultiVu 8261151
You stock your kitchen’s pantry shelves with quality food. Why would you skimp on the shelves of your bathroom cabinet? With cold and flu season upon us, it’s a great time to purge the medicine cabinet. Better to shop and prepare now than scramble when you are sick. Clean out clutter, get rid of anything that’s expired or you aren’t using, and stock up on the staples. A fresh start can make all the difference.
Well-known RN and health expert, Linda Ciampa has been helping families stay healthy for over a decade. On Wednesday, January 18th, Linda will be available for live interviews to share her best tips for preparing your medicine cabinet for the colder weather. She will also provide viewers with an easy-to-use option for keeping track of your family’s medical and fitness information.
Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services, commemorated its 50-year anniversary by awarding $150,000 in total grants to three organizations that share its goal to improve healthcare: The American Red Cross, the National Ovarian Cancer Coalition and Autism Speaks.
At a ceremony at the company’s flagship clinical laboratory in Teterboro, NJ, the company’s chairman, president and CEO Steve Rusckowski presented Health In Your Hands grants of $50,000 to representatives from each organization. Paul Brown, M.D., founder and former CEO of Quest’s predecessor company Metropolitan Pathology Laboratory, Inc. or MetPath, established in April, 1967, was also recognized at the event.
To view the multimedia release go to:
https://www.multivu.com/players/English/8080751-quest-diagnostics-50th-anniversary/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
A new survey from Alcon, the global leader in eye care and a division of Novartis, demonstrates that people experience significant emotional and lifestyle benefits after cataract surgery. Nearly three in four respondents who expressed an opinion agreed that after having the surgery, they were happier, more satisfied and had a greater appreciation for life. The survey also confirmed that life before surgery posed several daily challenges. A majority of survey respondents said cataracts made simple, day-to-day tasks harder, and made them feel annoyed, frustrated and old.
In recognition of Cataract Awareness Month this June, Alcon conducted the MyCataracts survey with 1,300 US adults, age 60 and over, who have undergone cataract surgery, to better understand the emotional journey of the condition and the lifestyle benefits of treatment. The survey expands Alcon’s ongoing MyCataracts awareness campaign by uncovering insights that will help people make informed treatment decisions together with their doctors.
To view the multimedia release go to:
https://www.multivu.com/players/English/8068751-alcon-pharmaceuticals-my-cataracts-eye-care/
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, will launch its latest advancement in comprehensive medication management, BD HealthSight™ platform for enterprise medication management, which offers a unique combination of connective technologies, analytics and expert services at this year's American Society of Health-System Pharmacists (ASHP) 2017 Midyear Meeting being held in Orlando from Dec. 3-7.
With direct medical costs associated with medication errors reaching $21 billion worldwide, innovative strategies must be developed to address the grand health challenges associated with medication management. BD has been evolving its focus to re-invent medication management with integration of the company’s technologies, analytics and expert services that aim to close the communication gaps across disparate solutions. The BD HealthSight platform connects systems and processes to help hospitals and health systems drive a safer, more efficient medication management process.
To view the multimedia release go to:
https://www.multivu.com/players/English/8198551-bd-healthsight-platform-ashp-2017/
LUNGevity, the nation’s leading lung cancer-focused nonprofit organization today launched a new mobile application designed to make understanding and living with lung cancer less daunting and considerably more manageable. The new Lung Cancer Navigator mobile app provides lung cancer patients with access to the latest medical and treatment information related to their specific lung cancer diagnosis, and serves as a convenient hub for organizing customized care and support networks, asking questions, describing and tracking symptoms, and managing multiple medications.
To view the multimedia release go to:
http://www.multivu.com/players/English/7865551-lungevity-lung-cancer-navigator-app/
Building on a successful campaign that helped hundreds of thousands of Americans learn their risk of developing type 2 diabetes through campaign messaging and an online risk test, the first-of-its-kind initiative to raise national awareness of prediabetes returns with an entertaining new approach. The new campaign, launching today, encourages viewers to take a one-minute prediabetes risk test to know where they stand and discover how they can decrease their risk of developing type 2 diabetes — and it does so with some adorable helpers.
More than one in three American adults has prediabetes — a serious health condition that often leads to type 2 diabetes and other significant health conditions like blindness, heart attack or stroke. According to newly released CDC data, however, nearly 90 percent of the 84 million people with prediabetes don’t know they have it and aren’t aware of the long-term risks to their health. Currently, about 30 million Americans are living with diabetes.
To view the multimedia release go to:
https://www.multivu.com/players/English/8142351-ad-council-prediabetes/
